KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $94.4 million.

  • Rigel Pharmaceuticals' Total Current Liabilities rose 7381.06% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 7381.06%. This contributed to the annual value of $63.3 million for FY2024, which is 1883.34% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Total Current Liabilities of $94.4 million as of Q3 2025, which was up 7381.06% from $86.6 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Total Current Liabilities peaked at $94.4 million during Q3 2025, and registered a low of $44.0 million during Q2 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Total Current Liabilities had a median value of $59.2 million in 2022 and averaged $60.5 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Total Current Liabilities plummeted by 2314.39% in 2023 and then surged by 7381.06% in 2025.
  • Rigel Pharmaceuticals' Total Current Liabilities (Quarter) stood at $63.6 million in 2021, then increased by 2.61% to $65.2 million in 2022, then dropped by 18.32% to $53.3 million in 2023, then rose by 18.83% to $63.3 million in 2024, then soared by 49.13% to $94.4 million in 2025.
  • Its last three reported values are $94.4 million in Q3 2025, $86.6 million for Q2 2025, and $66.6 million during Q1 2025.